QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

AFFIRM-1 trial did not meet primary endpoint or secondary endpointsCompany to conduct strategic review of portfolio and busines...

Core News & Articles

Maxim Group analyst Jason McCarthy maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target fro...

Core News & Articles

HC Wainwright & Co. analyst Joseph Pantginis reiterates Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and maintains $2...

Core News & Articles

Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly earnings of $6.55 per share. This is a 331.45 percent increase over los...

Core News & Articles

Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-116...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION